INTRODUCTION
Adeno-associated virus (AAV) is currently being used in several human gene therapy trials, including one targeting hemophilia B and another targeting cystic fibrosis, and to date has demonstrated persistent expression without inflammation of the target tissue. Some of the unique features that have distinguished AAV from other gene therapy vectors include (i) its ability to transduce both dividing and non-dividing cells; (ii) its broad tropism; (iii) its ability to integrate into a host chromosome or persist episomally, creating the potential for long-term expression; (iv) its status as a nonpathogenic virus; and (v) the lack of a cellmediated immune response. AAV vectors have successfully transduced many types of tissue including eye (34), muscle (56) , liver (63) , neurons (16), hematopoietic progenitors (59), gut (22), and keratinocytes (5). Therapeutic genes expressed by AAV vectors include factor IX (10,37, 40, 43, 63) , factor VIII (8), cystic fibrosis gene (CFTR) (27), brain-derived neurotrophic factor (23,42), glial cell line-derived neurotrophic factor (GDNF) (41, 46, 47) , and glutamic acid decarboxylase (45) , among others. Many exciting advances in the AAV field have occurred recently, directly impacting its utility in therapeutic gene delivery, including the development of vectors using alternative AAV serotypes, modification of the current capsids to allow either more restricted targeting of cells or a broader tropism, creative packaging strategies allowing portions of genes to be packaged in different viruses and overcoming the limited packaging capacity of AAV vectors, and alternative DNA packaging strategies overcoming one of the rate-limiting steps of transgene expression.
SAFETY OF AAV VECTORS
One of the first successes for gene therapy was treatment of children with severe combined immunodeficiency. However, recent news about the patient in France who has developed leukemia most likely as a result of the treatment has underscored the importance of vector safety. In this case, the patient developed cancer because of insertional mutagenesis; however, many of the problems associated with viruses used for therapeutic gene delivery have arisen because of the host defenses against viruses generated by the immune system. A handful of studies have focused on the type of immune response elicited by infection with both recombinant AAV (rAAV) and wildtype AAV (wtAAV) to understand the implications for therapeutic gene delivery. In one study, wtAAV was delivered intranasally, intramuscularly, or intravenously to rhesus macaques, and clinical and histopathological responses were evaluated. Sera from infected monkeys was collected 21 days post-infection and assayed for an in vitro anti-AAV neutralizing activity, and most of the infected animals did develop a significant neutralizing-antibody response. However, lymphocytes from these animals did not proliferate when exposed to AAV capsid antigen ex vivo unless the animal had also been exposed to adenovirus at the time of AAV infection. Histological examination of wtAAV-infected tissue in all of the groups of infected monkeys showed no indication of inflammation or cellular infiltration (35). This type of response was also observed in repeated delivery of AAV vectors to the rabbit airway. After repeated delivery of rAAV-cystic fibrosis (CF) transmembrane conductance regulator (CFTR), rabbits developed high titers of AAV-neutralizing antibody, but this did not seem to affect subsequent expression of GFP when that was later delivered by rAAV. In addition, no significant inflammatory response was observed due to repeated exposure of the airway to rAAV-CFTR or rAAV-GFP (3). The studies described above, along with others not described here, indicate that wtAAV is capable of generating a humoral immune response, but not any significant toxicity or cell-mediated immune response. In most animal models and clinical trials using AAV vectors, long-term transgene expression has been described to occur without eliciting an immunological response to the transgene product (32, 36, 37, 40, 62, 70) . This is in contrast to other viral vectors such as adenovirus where strong cellular immune response to both the vector and transgene has been observed (38, 66, 74) .
There have been some studies, however, where rAAV vectors have been used successfully for vaccination and have been demonstrated to elicit both cellular and humoral immune responses to the encoded transgene (6,21,44,48). Subsequent work by Sarukhan et al. (61) indicates that rAAV-injected animals might be able to take up antigenic material released from transduced cells and subsequently activate T-cells through cross-presentation, but antigenpresenting cells are probably not directly tranduced. If cross-presentation is minimized by strategies to control trangene production and utilization, then the cellular immune response should not be as much of an issue with AAV vectors. Other viral vectors, such as those based on adenovirus, are able to directly transduce dendritic cells in vivo, leading to expression of the transgene within antigen-presenting cells. One consequence of this difference is that protocols designed to interfere with the immune response by blocking antigen presentation or by inducing transgene-specific T-cell tolerance were successful with rAAV but not with adenovirus vectors (61) . These types of observations underlie the importance of understanding the immune response of the cell and animal to viral vectors.
The role of the virion shell in viral pathogenesis is also relatively unknown, and the use of viral vectors in human gene transfer experiments requires an understanding of these interactions. In a recent study in our laboratory, DNA microarrays were used to identify genes whose expression is modulated during pathogenic adenovirus or nonpathogenic AAV infections. Responses to wild-type viruses, recombinant vectors, or empty virion particles were compared. Interestingly, AAV shells induced nearly the full complement of changes elicited by the intact virus. Furthermore, the cellular genes affected correlated with a nonpathogenic response, with anti-proliferative genes being induced as a cluster. In contrast, infection with a first-generation adenovirus vector yielded a much broader response, including induction of immune and stress-response genes associated with pathogenic effects. These results suggest that the majority of changes that are observed with infection with AAV vectors are set in motion from the process of infection itself. In addition, a relatively small number of cellular genes show changes in expression (38 of 5600 mRNAs showed greater than 4-fold change in level at 48 h post-infection), suggesting that AAV infection has a relatively minor impact on the cell. Of course, one of the major concerns with the use of viruses for gene therapy vectors is their safety, especially when large quantities are typically required for therapeutic gene delivery. AAV has an advantage compared to more typical viruses because the wild-type virus has never been associated with any disease and it is defective for the ability to replicate in an infected cell. Additionally, as outlined above, it does not appear to elicit a cell-mediated immune response, and where it has been used in gene therapy trials to date, it has not been associated with inflammation of the target tissue. Finally, DNA microarray studies have indicated that it has minimal influence on changing cellular gene expression. These data indicate that AAV has a good safety profile for a virus to be used as a gene delivery vehicle for clinical applications.
THERAPEUTIC GENE DELIVERY
AAV has shown promise as a vector in the delivery of genes to treat several diseases. Most notably, it has shown potential for the treatment of hemophilia A and B, CF, Parkinson's disease, and more recently Canavan Disease (a rare neurological disorder). One of the first applications of AAV for therapeutic gene delivery was focused on CF, and clinical trials have been enrolling patients since 1996 (26).
DRUG DISCOVERY AND GENOMIC TECHNOLOGIES
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Many improvements in the treatment of this disease have occurred recently, but conventional treatments do not treat the underlying cause of the disease, a dysfunctional CFTR. A therapy that can introduce a corrected copy of the CFTR gene would clearly be preferable to current therapies. In a Phase II clinical trial using tgAAVCF, an AAV vector containing a complete copy of the human CFTR gene (15,27,28,68), there was no evidence of inflammation or any other toxic effects associated with administration to the maxillary sinus compared to placebo treatment to the contralateral maxillary sinus (67) . Currently, patients in at least eight centers are enrolled in Phase II gene therapy trials with tgAAVCF, and these studies are ongoing (51) .
Gene therapy also shows great promise for the treatment of hemophilia A and B where the goal is sustained expression of factor VIII and factor IX, respectively. Treatment of hemophilia A requires sustained expression of factor VIII protein, and this has been achieved with intraportal injection of AAV carrying human factor VIII into mice with no pathology (8,12). In hemophilic canine models, intramuscular injection of AAV with the canine factor IX (FIX) gene has resulted in plasma FIX levels of 1%-2%, a level that would be therapeutic in patients with hemophilia B (10,37). In a more recent study (52) also using canine models, but with gene transfer directed within the liver, the authors observed expression levels that were near the curative range at low vector doses. Phase I clinical trials in patients with severe hemophilia B are ongoing where AAV-hFIX has been administer into the hepatic artery via arteriography, and to date no toxicity has been observed (the National Hemophilia Foundation's fifth workshop on gene therapies for hemophilia).
AAV transduces neurons and therefore has shown promise in the treatment of diseases of the brain such as Parkinson's disease. In initial studies, AAV vectors expressing genes for dopamine production (tyrosine hydroxylase and aromatic amino acid decarboxylase) were used to transduce striatal cells of dopamine-depleted monkeys, and there was no significant toxicity, but significant phenotypic effects were not observed (20). In a later study, using a parkinsonian rat model, an AAV vector expressing tyrosine hyrdroxylase combined with one expressing GTP-cyclohydrolase-1 was used for gene transfer; in contrast to the earlier study, substantial improvements in motor behavior was observed (30). The improvement in results may have been a result of the difference in strategy or the progression of protocols to produce higher-titer AAV vectors.
Neuroprotective strategies have also been proposed for Parkinson's disease, since symptoms such as rigidity, tremors, and akinesia start to appear when about 50% of the dopamine neurons in the substantia nigra have degenerated. In a study using a parkinsonian rat model, GDNF was selected as a neuroprotective gene therapy model because neurotrophic factors can interfere with both apoptosis and necrosis, as well as protect cells from toxic damage. This study demonstrated sustained GDNF expression over a 3-to 6-month period in the substantia nigra, and this expression allowed both regeneration and significant functional recovery in these rats (4). Most recently, in a study by Luo et al. (45) , strong protection of nigral dopamine neurons and rescue of the parkinsonian behavioral phenotype was observed in a rat parkinsonian model when AAV was used to express glutamic acid decarboxylase (the enzyme that catalyzes the synthesis of the neurotransmitter) within neurons in the subthalamic nucleus in these animals.
There are many applications for AAV in therapeutic gene delivery, and some have been outlined above. There are still a few limitations in the use of AAV as a gene therapy vector that many laboratories are working to overcome by many creative strategies. Some of these strategies are discussed below.
DEVELOPMENT OF VECTORS BASED ON ALTERNATIVE AAV SEROTYPES
In all of the clinical trials to date, the prototypic AAV type 2 (AAV2) virus has been used, but it has become apparent that other AAV serotypes have utility in gene transfer. There are seven identified AAV serotypes. AAV1 to AAV4 were originally identified as contaminants of adenovirus preparations, while AAV5 was isolated from a human condylomatous wart (1, 13, 14, 53, 60, 64, 72) . More recently, two novel serotypes, AAV7 and AAV8, were virus (helper viruses) (7). Therefore, these other serotypes of AAV are also classified as nonpathogenic and should share a safety profile similar to AAV2 (7). Each of these different serotypes of virus has a natural tropism that is distinct and that limits its utility for gene transfer in certain tissue types. For example, AAV1 has been shown to be more efficient in the transduction of liver and muscle than AAV2 (9,57,72) and perhaps might be better suited as a gene delivery vehicle for diseases requiring expression of normal gene product in these tissues. Additionally, it was recently shown that AAV5 and AAV3 transduce liver and muscle better than AAV2 across several different strains of rodents and routes of injection (57) . In the same study, AAV5 and AAV4 were found to transduce rat retina most efficiently, followed by type 1 (Figure 1 ). Earlier studies have demonstrated that variant cell types within the central nervous system can be transduced more effectively with alternative AAV serotypes (75) . These types of studies underscore the importance of understanding the tropism of the various AAV serotypes so that they can be fully exploited to maximize the efficiency of gene delivery to various tissue types. Many groups are now pursuing detailed analyses of the alternative cellular receptors and the pathways that these viruses take to the nucleus of the cell where the viral genome (or transgene) is expressed (16,17,39,57,60,69,75). Subsequent sections will discuss the prototypic AAV2.
DEVELOPMENT OF TARGETING VECTORS
The tropism of AAV has either been limited to particular cell types or expanded to include other cell types by modifying the capsids in ways that target alternative cellular receptors. There are two main strategies that have been used: chemically cross-linking bifunctional antibodies and genetic modification of the capsid. AAV2 has been targeted to a nonpermissive cell line by cross-linking a bispecific F(ab′γ) 2 antibody that had specificity for both the virion of AAV and the surface receptor α IIb β 3 integrin (2). When nonpermissive cells (human megakaryoblasts) were exposed to AAV that had been preincubated with this bispecific antibody, the virus transduced these cells. This AAV that had been preincubated with the antibody could also transduce HeLa cells, a permissive cell line, demonstrating an expansion of the host range with this approach.
In employing the second strategy, genetically altering the capsid coding region, most of the work to date has been done in the absence of a crystal structure for AAV. For this strategy to be successful, predictions must be made regarding the location of domains on the surface of the virion. These predictions have been made using several strategies that have been reviewed by Rabinowitz et al. (58) . In an attempt to expand the tropism of AAV, Girod et al. with an RGD motif) into the capsid coding region, thereby allowing cells that are nonpermissive for AAV infection, mouse melanoma B16 cells, to be transduced. The insertion of the serpin receptor ligand into the AAV capsid was another strategy employed to alter AAV tropism (71) . Grifman et al. (33) have demonstrated that the incorporation of the peptide motif NGR into the AAV capsid alters the tropism of the virus so that it targets cells that express the CD13 receptor, which is found in many tumor cell lines and in angiogenic vasculature. These types of strategies have been given a tremendous advantage by the recent publication of the atomic structure of AAV2 (Figure 2 ) (73) . Subsequent approaches will likely incorporate this new knowledge and allow rational vector design towards the development of targeting vectors.
SIGNIFICANT IMPROVEMENTS OF AAV VECTORS
Self-Complementary AAV Vectors
The DNA in the AAV virion is single-stranded, and one of the rate-limiting steps from the infection of the virus to expression of the protein is conversion of the single- It has been difficult to achieve stable transduction in the liver with conventional AAV vectors, and it has been recently reported (55) that, even at very high doses of vector (up to 1.8 × 10 12 particles/mouse), at most only 10% (and typically 5%) of hepatocytes are transduced in mice. McCarty et al. (49) were able to achieve transduction levels of greater than 25% in mouse liver using the scAAV vectors (Figure 3 ) with 5 × 10 9 particles of virus/mouse, a significant improvement over conventional single-stranded vectors (personal communication).
Dimerized AAV Vectors
One limitation of AAV has been the packaging constraint of the vector, and several groups have tried to overcome this by splitting genes into two parts and then packaging these parts into two separate AAV vectors. Recombinant AAV is found in various forms in transduced cells, including circular concatemers and linear concatemers in a preferred head-to-tail orientation (10,18,50). Several groups have exploited this feature of AAV to deliver genes larger than the packaging capacity of a single AAV vector. For example, Sun et al. (65) split the lacZ gene into two AAV vectors, each carrying an intron and an appropriate splicing signal; when these two vectors were used to infect cells in vitro and in vivo, both the full-length mRNA and the transgene protein were produced. Nakai et al. (54) used a similar strategy successfully to express human elongation factor α in mice, and Duan et al. (19), using this strategy, expressed luciferase with divided genes in AAV vectors in mice. One of the issues in using AAV for gene delivery to treat hemophilia A is that human factor VIII cDNA is 7 kb larger than the packaging capacity of the virus. Chao et al. (11) have reported the use of this strategy to deliver factor VIII successfully in mice and showed correct head-to-tail vector dimerization and sustained factor VIII expression for four months. The two improvements in AAV vectors discussed above have directly addressed what has been previously viewed as impediments to the development of these vectors for gene therapy, namely (i) limited transduction in some tissues because of the rate limiting step of complementary-strand synthesis and (ii) the DNA packaging constraints of the virus.
CONCLUSIONS
AAV vectors have distinguished themselves from other gene delivery vectors mainly because of their status as being derived from a nonpathogenic virus and their inability to replicate without the presence of helper virus. This will continue to distinguish these vectors as they are developed for clinical use. The last few years have been very exciting ones in the AAV field, as our understanding of the tropism of other AAV serotypes has continued to grow, and now these can be added to our arsenal of gene delivery vehicles. Additionally, the crystal structure of AAV is now known, and rational vector design can now be performed so that specific cell types can be targeted while the normal tropism can be disrupted. Our knowledge of how best to utilize this virus to deliver genes efficiently to only the cells in an organism where the gene is needed is developing rapidly, and, hopefully, some of this knowledge will translate into an effective treatment for people with genetic diseases such as hemophilia, CF, Parkinson's disease, and the many others. Chiorini. 2001. Adeno-associated virus serotype 4 (AAV4) and AAV5 both require sialic acid binding for hemagglutination and effi-
